Literature DB >> 20177649

Omics-based medicine and systems pathology. A new perspective for personalized and predictive medicine.

H Tanaka1.   

Abstract

OBJECTIVES: Recent important advances in the human genomics and post-genomic "omics" are now bringing about a new medical care which we call "omics-based medicine". In this article, we investigated the development and future possibilities of omics-based medicine.
METHODS: We divided the development of omics-based medicine into three generations in order to clarify the main clinical goals and characteristics of informatics method of each generation, together with its future possibilities.
RESULTS: The first generation of omics-based medicine started with "genomic medicine" based on the inborn individual differences of genome. It has opened the study of genetic polymorphism of the diseases and promoted the personalized medication based on the pharmacogenetic/pharmacogenomic difference of the drug response. In the second generation of omics-based medicine, owing to the advances in the high-throughput technology, vast amount of the various post-genomic disease omics data containing comprehensive molecular information of diseased somatic cells has become available. It reflects the ongoing state of diseases more closely and enables the predictive medicine such as prognosis prediction of disease by applying the data-driven analysis. Finally, due to the rapidly growing knowledge about the cellular molecular network, system-level understanding of the disease, called systems pathology, becomes possible. It can fully exploit the substantial contents of disease omics and will lead to a comprehensive understanding of disease process by using model-driven analysis.
CONCLUSION: Omics-based medicine and systems pathology will realize a new personalized and predictive medicine.

Entities:  

Mesh:

Year:  2010        PMID: 20177649     DOI: 10.3414/ME9307

Source DB:  PubMed          Journal:  Methods Inf Med        ISSN: 0026-1270            Impact factor:   2.176


  5 in total

1.  Use of Metabolomics to Trend Recovery and Therapy After Injury in Critically Ill Trauma Patients.

Authors:  Brodie A Parent; Max Seaton; Ravi F Sood; Haiwei Gu; Danijel Djukovic; Daniel Raftery; Grant E O'Keefe
Journal:  JAMA Surg       Date:  2016-07-20       Impact factor: 14.766

Review 2.  Genetic basis and detection of unintended effects in genetically modified crop plants.

Authors:  Gregory S Ladics; Andrew Bartholomaeus; Phil Bregitzer; Nancy G Doerrer; Alan Gray; Thomas Holzhauser; Mark Jordan; Paul Keese; Esther Kok; Phil Macdonald; Wayne Parrott; Laura Privalle; Alan Raybould; Seung Yon Rhee; Elena Rice; Jörg Romeis; Justin Vaughn; Jean-Michel Wal; Kevin Glenn
Journal:  Transgenic Res       Date:  2015-02-26       Impact factor: 2.788

3.  Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings.

Authors:  Agnieszka Latosinska; Manousos Makridakis; Maria Frantzi; Daniel M Borràs; Bart Janssen; William Mullen; Jerome Zoidakis; Axel S Merseburger; Vera Jankowski; Harald Mischak; Antonia Vlahou
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

4.  Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance.

Authors:  Michael A Schmidt; Thomas J Goodwin
Journal:  Metabolomics       Date:  2013-06-27       Impact factor: 4.290

5.  HiGHmed - An Open Platform Approach to Enhance Care and Research across Institutional Boundaries.

Authors:  Birger Haarbrandt; Björn Schreiweis; Sabine Rey; Ulrich Sax; Simone Scheithauer; Otto Rienhoff; Petra Knaup-Gregori; Udo Bavendiek; Christoph Dieterich; Benedikt Brors; Inga Kraus; Caroline Marieken Thoms; Dirk Jäger; Volker Ellenrieder; Björn Bergh; Ramin Yahyapour; Roland Eils; HiGHmed Consortium; Michael Marschollek
Journal:  Methods Inf Med       Date:  2018-07-17       Impact factor: 2.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.